JPMorgan Chase & Co. reissued their underweight rating on shares of Sanofi (NYSE:SNY) in a report released on Thursday.

Analyst Recommendations for Sanofi (NYSE:SNY)

SNY has been the subject of several other research reports. Zacks Investment Research downgraded shares of Sanofi from a buy rating to a hold rating in a research report on Monday, June 6th. Citigroup Inc. reiterated a neutral rating on shares of Sanofi in a research note on Tuesday, June 28th. Jefferies Group reiterated a hold rating on shares of Sanofi in a research note on Wednesday, September 14th. TheStreet upgraded Sanofi from a hold rating to a buy rating in a research note on Wednesday, July 27th. Finally, BNP Paribas upgraded Sanofi from an underperform rating to a neutral rating in a research note on Tuesday, September 13th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company. Sanofi presently has an average rating of Hold and an average price target of $60.50.

Sanofi (NYSE:SNY) opened at 38.97 on Thursday. The firm has a 50-day moving average of $39.51 and a 200 day moving average of $40.65. The firm has a market capitalization of $100.31 billion, a PE ratio of 21.61 and a beta of 1.01. Sanofi has a 52 week low of $37.41 and a 52 week high of $51.88.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dodge & Cox raised its position in Sanofi by 3.0% in the second quarter. Dodge & Cox now owns 55,155,913 shares of the company’s stock worth $2,308,275,000 after buying an additional 1,625,784 shares during the last quarter. Franklin Resources Inc. raised its position in Sanofi by 13.3% in the first quarter. Franklin Resources Inc. now owns 21,232,196 shares of the company’s stock worth $852,684,000 after buying an additional 2,500,421 shares during the last quarter. Fisher Asset Management LLC raised its position in Sanofi by 0.7% in the second quarter. Fisher Asset Management LLC now owns 13,638,183 shares of the company’s stock worth $564,894,000 after buying an additional 91,233 shares during the last quarter. Hotchkis & Wiley Capital Management LLC raised its position in Sanofi by 12.5% in the second quarter. Hotchkis & Wiley Capital Management LLC now owns 11,432,112 shares of the company’s stock worth $478,434,000 after buying an additional 1,267,118 shares during the last quarter. Finally, Boston Partners raised its position in Sanofi by 10,203.3% in the second quarter. Boston Partners now owns 7,402,009 shares of the company’s stock worth $309,774,000 after buying an additional 7,330,168 shares during the last quarter. 9.42% of the stock is currently owned by hedge funds and other institutional investors.

About Sanofi

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.

5 Day Chart for NYSE:SNY

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.